Suzanne R. Hayman

Mayo Clinic — United States

Medicine · Health Sciences

85h-index27.8kcitations882works1.92yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Multiple Myeloma Research and Treatments(503), Amyloidosis: Diagnosis, Treatment, Outcomes(284), Protein Degradation and Inhibitors(158), Chronic Lymphocytic Leukemia Research(127), Cancer Treatment and Pharmacology(110)

Publications879 total

Prognostic value of immunoparesis, lymphopenia, high serum ferritin, and suppression of the non-involved serum free light chains (niFLC) in relapsed and refractory multiple myeloma patients (RRMM) receiving bispecific antibodies
Blood·2025Open Access
Clinical course, predictors of development, and therapeutic response in multiple myeloma with central nervous system involvement
Blood·2025Open Access
Self-reported geriatric impairments and treatment toxicity in older patients with multiple myeloma - a single center prospective study
Blood·2025Open Access
Patterns of progression and clinical outcomes after first relapse in patients with primary plasma cell leukemia
Blood·2025Open Access
Disease characteristics, treatment patterns, and outcomes of AL amyloidosis patients with high-risk FISH cytogenetics
Blood·2025
Radiomics-based identification of high-risk disease in newly diagnosed multiple myeloma
Blood·2025Open Access
AL amyloidosis: a real-world experience with CAR T-cell therapy
Blood Advances·2025Open Access
Clinical Characteristics, Treatment Responses and Outcomes of Light Chain Multiple Myeloma
American Journal of Hematology·2025
Impact of residual clonal plasma cells in S-phase at the time of autologous stem cell transplantation on clinical outcomes
Blood Cancer Journal·2025Open Access
Refining PET-based response in extramedullary multiple myeloma using total lesion glycolysis
Leukemia·2025
Performance of Deauville Score and Total Lesion Glycolysis as Response Markers for Multiple Myeloma with Extramedullary Disease
Clinical Lymphoma Myeloma & Leukemia·2025
Value of serum-free light chain measurements in response and progression assessment in multiple myeloma with monoclonal protein measurable by electrophoresis
Blood Cancer Journal·2025· 1 citedOpen Access
Lymphocyte Kinetics and Outcomes of Chimeric Antigen Receptor T Cell Therapy in Multiple Myeloma With Out of Specification Products
American Journal of Hematology·2025Open Access
Interleukin-6 is a highly prognostic biomarker for POEMS syndrome
Leukemia·2025· 2 citedOpen Access
From CyBorD to dara-CyBorD, ASCT utilization trends in AL amyloidosis: a 15-year analysis
Blood Advances·2025· 1 citedOpen Access
Hepatic involvement in light chain amyloidosis: analysis of 130 patients and predictors of hepatic response and survival
Amyloid·2025· 4 citedOpen Access
Eliminating The Need for Sequential Confirmation of Response in Multiple Myeloma
Blood·2025· 1 cited
Erratum: Outpatient Management of Bispecific Related Toxicities: An Observational Study of Safety Outcomes and Resource Utilization
JCO Oncology Practice·2025
Patterns and clinical significance of high-risk secondary cytogenetic abnormalities at first relapse in multiple myeloma.
Journal of Clinical Oncology·2025
Bone marrow polyclonal plasma cells in myeloma post-treatment: Implications on outcome and effect of therapy.
Journal of Clinical Oncology·2025
page 1 of 44Next →

Frequent Co-authors

Angela Dispenzieri(46), Morie A. Gertz(46), Martha Q. Lacy(45), Shaji Kumar(43), S. Vincent Rajkumar(43), John A. Lust(35), Robert A. Kyle(35), Stephen J. Russell(33), Steven R. Zeldenrust(31), Francis K. Buadi(30), David Dingli(29), Philip R. Greipp(26), Rafaël Fonseca(23), Thomas E. Witzig(21), Nelson Leung(17), Vivek Roy(16), Craig B. Reeder(12), P. Leif Bergsagel(12), Prashant Kapoor(11), Joseph Mıkhael(11)